OncoCyte Corp 4
4 · OncoCyte Corp · Filed Jun 19, 2017
Insider Transaction Report
Form 4
Redmond Cavan M.
Director
Transactions
- Award
Option to Purchase Common Stock
2017-06-15+6,520→ 6,520 totalExercise: $5.10Exp: 2027-06-14→ Common Stock (6,520 underlying) - Award
Option to Purchase Common Stock
2017-06-15+20,000→ 20,000 totalExercise: $5.10Exp: 2027-06-14→ Common Stock (20,000 underlying)
Footnotes (2)
- [F1]Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018.
- [F2]Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017.